Kristen Phillips, director of Golden Section Studios, and Brooke Waupsh, founding CEO of Swoovy — the program's inaugural startup in residence — join the Houston Innovators Podcast to discuss how they are collaborating on a new B2B volunteer platform. Photos courtesy

Brooke Waupsh wanted to change the way people volunteered and help increase access to volunteers for nonprofits. So, she launched Swoovy, a dating app that connected singles who wanted to do some good on their first dates. Now, the Austin-based company is looking to expand to connect corporates with community service opportunities.

As Swoovy works on this new B2B SaaS platform, it's tapped a new partner to help support its endeavors. Golden Section Studios has launched to focus on advancing and supporting early-stage software companies like Swoovy, which is its inaugural startup in residence.

"We had discussions around our vision for Swoovy and the momentum behind the business we'd had in the early stages in Austin and looking for strategic growth partners, investors, and resources," Waupsh says on this week's episode of the Houston Innovators Podcast. "We had an instant relationship that we developed with the Studios as they were looking to launch this program."

Waupsh says that in addition to the financial support that comes with the arrangement — GSS plans to contribute up to $500,000 in its member companies — the Studios will offer Swoovy the chance to grow and scale, without having to hire a huge team right out of the gate.

"What's unique about the Studios for us is that as a startup and a small team, we have the bandwidth and a higher capacity to move faster on all cylinders — sales, marketing, technology — without having to staff up a team of 20," Waupsh says.

Kristen Phillips, director of Golden Section Studios, says that for years, Golden Section Technology — and its accompanying venture arm — has worked to develop SaaS technology and has created a large network of experts and mentors — all of whom will be made available to each of GSS's future member companies like Swoovy.

Additionally, Phillips says her team has a lot of lessons learned to share with the companies they will support.

"When you're dealing with early-stage companies, a lot of it just boils down to product-market fit and making sure you're able to develop a technology that's scalable that works with your customers as you scale," Phillips says on the podcast. "It sounds simple, but it's not easily mastered."

Startups also looking for this sort of guidance can learn more online and even apply to the program. In the meantime, GSS and Swoovy alike are focusing on the new technology that can really be a gamechanger for both corporates looking to provide volunteer opportunities as well as nonprofits with a huge need for workers.

"We're just excited to have the SaaS B2B platform coming out with Golden Section Studios and expand on empowering more people through businesses to be able to have access to a tool like this," Waupsh says.

Waupsh and Phillips share more about the their partnership and other major SaaS challenges on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”